Role of TIM Molecules in Regulatory and Inflammatory B cells in Allo andAutoimmunity

TIM 分子在同种异体和自身免疫中调节性和炎症性 B 细胞中的作用

基本信息

项目摘要

In addition to humoral immunity, B cells play an important role shaping T effector responses through antigen presentation, costimulation, and cytokine production. Thus, B cell depletion ameliorates autoimmune diabetes and arthritis in mice, and rapidly improves RA and MS in humans, and outcomes do not correlate with fall in autoantibodies. In contrast, in both humans and mice, B cell depletion can also worsen autoimmunity, and can promote acute rejection and chronic vasculopathy in renal and cardiac transplant patients, respectively. These studies indicate that B cells can either enhance, or inhibit, inflammatory responses. In this regard, transfer of various B cell subsets can inhibit autoimmunity and allograft rejection through IL-10, and a growing list of other mechanisms. However, lack of a universal phenotype or master transcription factor (TF) for these Bregs has stymied the field. It is unknown whether these disparate cells are distinct or inter-related, or what regulates their differentiation or cytokine expression. Our preliminary data show that: 1) TIM-1 is an inclusive marker for IL-10+ Bregs. 2) Intact TIM-1 signaling on B cells regulates the expression of both TFs and various regulatory molecules (“regulatory module”). This allows us to test their role in Breg differentiation and function. 3) We also show that CpG-activated Pro-B cells transfer exceeding potent suppression, mediated by mature Breg progeny exhibiting different mechanisms of action in different locations. Both progenitors and progeny are TIM-1+, which allows us to examine the role of TIM-1 and TFs in Breg differentiation and regulatory module expression. B cells can also express various proinflammatory cytokines in autoimmune and infectious settings that strongly promote inflammatory responses. No phenotype for such effector B cells (Beff) has been established, and it is unclear whether the various cells described, are distinct or inter-related. Major aspects of Beff biology are completely unknown, including how differentiation and cytokine expression are regulated. We have discovered that: 1) TIM-4 identifies Beff that express IFNγ and IL-17 and accelerate allograft rejection. 2) IL-17 is notably, both a potent effector cytokine, and is also required for development of the Beff inflammatory program. Loss of B cell IL-17 not only reverses their inflammatory role, but also, inhibits the immune response, promoting allograft tolerance. 3) TIM-4 ligation inhibits proinflammatory cytokine expression. Based on our novel preliminary data, this PPG will utilize autoimmune and allograft models to test the central hypothesis that TIM-1 and TIM-4, respectively, are unifying markers for Bregs and Beff and regulate expression of TFs and other molecules important for their development and function. This will be addressed in 3 interactive and mutually supportive projects: Project 1: Role of Tim-1 and Bregs in Tolerance and Auto- immunity; Project 2: Immunoregulation by TLR-activated TIM-1+ ProB Cells in Transplantation; and Project 3: Inflammatory B Cells Defined by TIM-4 in the Alloimmune Response. This understanding is key to developing clinically relevant approaches to selectively target Beff and Bregs to enhance or inhibit the immune response.
除了体液免疫外,B细胞通过抗原形成T效应应答也起着重要作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID M ROTHSTEIN其他文献

DAVID M ROTHSTEIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID M ROTHSTEIN', 18)}}的其他基金

Role of TIM Molecules in Regulatory and Inflammatory B cells in Allo andAutoimmunity
TIM 分子在同种异体和自身免疫中调节性和炎症性 B 细胞中的作用
  • 批准号:
    9751742
  • 财政年份:
    2018
  • 资助金额:
    $ 187.07万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10455066
  • 财政年份:
    2018
  • 资助金额:
    $ 187.07万
  • 项目类别:
Inflammatory B cells defined by TIM-4 in the Alloimmune response
同种免疫反应中 TIM-4 定义的炎症 B 细胞
  • 批准号:
    10214481
  • 财政年份:
    2018
  • 资助金额:
    $ 187.07万
  • 项目类别:
Immunoregulation by TLR-activated TIM-1+ ProB Cells in Transplantation
TLR 激活的 TIM-1 ProB 细胞在移植中的免疫调节
  • 批准号:
    10455069
  • 财政年份:
    2018
  • 资助金额:
    $ 187.07万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10214476
  • 财政年份:
    2018
  • 资助金额:
    $ 187.07万
  • 项目类别:
Immunoregulation by TLR-activated TIM-1+ ProB Cells in Transplantation
TLR 激活的 TIM-1 ProB 细胞在移植中的免疫调节
  • 批准号:
    10214480
  • 财政年份:
    2018
  • 资助金额:
    $ 187.07万
  • 项目类别:
Role of TIM Molecules in Regulatory and Inflammatory B cells in Allo andAutoimmunity
TIM 分子在同种异体和自身免疫中调节性和炎症性 B 细胞中的作用
  • 批准号:
    10455065
  • 财政年份:
    2018
  • 资助金额:
    $ 187.07万
  • 项目类别:
Inflammatory B cells defined by TIM-4 in the Alloimmune response
同种免疫反应中 TIM-4 定义的炎症 B 细胞
  • 批准号:
    10455071
  • 财政年份:
    2018
  • 资助金额:
    $ 187.07万
  • 项目类别:
Inflammatory B Cells Defined by TIM-4 in the Alloimmune Response
TIM-4 在同种免疫反应中定义的炎症 B 细胞
  • 批准号:
    9542016
  • 财政年份:
    2017
  • 资助金额:
    $ 187.07万
  • 项目类别:
In Vivo Detection And Mechanisms Of Regulatory B Cell Function In Transplantation
移植中调节性 B 细胞功能的体内检测和机制
  • 批准号:
    9197259
  • 财政年份:
    2015
  • 资助金额:
    $ 187.07万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 187.07万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 187.07万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 187.07万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 187.07万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 187.07万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 187.07万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 187.07万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 187.07万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 187.07万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 187.07万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了